EMD Serono Collaborates with Sutro Biopharma to Develop ADCs
EMD Serono announces a collaboration with Sutro Biopharma to develop antibody drug conjugates for multiple undisclosed targets.
On Sept. 17, 2014, EMD Serono, a subsidiary of Merck KGaA, and Sutro Biopharma, a San Francisco biopharmaceutical company developing antibody drug conjugates and bispecific antibodies, announced a collaboration and license agreement to develop antibody drug conjugates (ADCs).
EMD Serono will combine their knowledge of target biology with Sutro’s technology platforms in its oncology programs to develop ADCs. Both companies believe that ADCs have the potential to specifically target and deliver cytotoxic drugs to cancer cells, while safeguarding healthy tissue.
Sutro’s cell-free protein synthesis platforms will allow the companies to discover and develop multiple ADCs. Sutro will be responsible for delivering ADCs for Phase I clinical trials. EMD Serono will be responsible for clinical development and commercialization of any resulting products. EMD Serono will also be responsible making an upfront payment to Sutro and for funding R&D activities.
Source: EMD Serono
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
